Oxygenated ovaries: CaDi launches “powerful” omega 3-based supplement to balance hormones

05 Jan 2021 --- Biotech company Cambridge Diagnostic Imaging (CaDi) is releasing Lycovary Daily, a supplement that boosts tissue oxygenation and respiration in the ovaries to combat common hormonal health problems in women.

Lycovery is a complex of docosahexaenoic acid (DHA) with the carotenoid molecules lutein and zeaxanthin, which, says the company, can provide targeted anti-aging oxygenation for women throughout their life.

Oxygenation essential for balancing hormones
Hundreds of millions of women encounter problems before and during their periods due to ovarian hormonal imbalances. Hot flushes and night sweats during menopause, early onset of osteoporosis and other later life issues also stem from these imbalances.

This is due to tissue oxygenation, which is essential for all tissue functions, including hormone production.

Tissue oxygenation gradually declines with age. However, tissue oxygen deprivation can occur at any point, often caused by dietary deficiencies, negative lifestyle factors or inflammatory conditions. 

This, in turn, can lead to disruption in synchronization of the ovarian hormone cascade.

Lycovery is designed for daily use for all women starting from the fertile phase for ovarian protection.A life-long supplement 
In response, CaDi has developed the supplement designed for daily use “from the beginning of their fertile phase to menopause.”

“We designed Lycovery to help women support their health and improve the quality of their lives,” says Alexey Shulepov, CEO of CaDi. 

“Many years of medical research have now resulted in a powerful and effective dietary supplement, which will be available worldwide from the beginning of next year.”

Clinical trial results 
A clinical study led by Lycotec, the research arm of CaDi, showed that 250 mg of Lycovary Daily DHA Omega 3 is between 10 to 16 times stronger than conventional omega 3 supplement products and four to five times more potent than standard omega 3 pharmaceuticals. 

CaDi says this superiority translates into a much more efficient reduction in markers of inflammatory damage and a boost in peripheral tissue oxygenation and respiration in the ovaries. 

The targeted delivery and increased bioavailability that results also reduces possible side effects of supplementation and eliminates unnecessary overconsumption of traditional omega 3 and carotenoid products – something CaDi says is all too common. 

Personalized AI supplementation 
In line with the ever-growing personalized health market, CaDi’s products are offered as part of individualized remedies. 

This is conducted using AI-based algorithms developed by the company to determine correct doses on a patient by patient basis. Up to half of women experience adverse menopausal symptoms.

Dr. Ivan Petyaev, founder and CEO of Lycotec spoke to NutritionInsight last year, saying: “Different people respond differently to treatments. We need to devise different formulations for different age groups and different body weights. These are not products to be simply sold on shop shelves.”

He said CaDi also uses the data accumulated from treatments and repeat checkups to further its research and product development. 

Lycovery is GMO-free and vegan. 

Lucrative ovarian market 
CaDi is a member of the International Association of Fertility Societies, which campaigns to combat the ovarian health problems affecting over half of the world’s female population. 

Around 30 to 40 percent of women of reproductive age have premenstrual syndrome (PMS), and about 50 percent dysmenorrhea, of whom 15 to 20 percent have severe painful periods. 

Another 45 to 50 percent of all women have adverse menopausal symptoms.

These statistics provide evidence of a largely untapped and under-researched market for supplementation, says CaDi, especially as a way to tackle the increasing rates of comorbid metabolic issues arising from some lifestyles. 

Edited

By Louis Gore-Langton